160 related articles for article (PubMed ID: 10212757)
1. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
Chang SC; Fang CT; Hsueh PR; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
3. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
5. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
6. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
Tenover FC; Baker CN
J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
[TBL] [Abstract][Full Text] [Related]
7. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
10. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
[TBL] [Abstract][Full Text] [Related]
13. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
